Press release
Anti-Inflammatory Drugs Market to Reach US$ 198.92 Billion by 2031, Driven by Rising Prevalence of Autoimmune Disorders and Biosimilar Growth | DataM Intelligence
Anti-Inflammatory Drugs Market
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/anti-inflammatory-drugs-market?jd
United States Key Industry Developments
☑️ January 2026: AbbVie continued strong performance of Skyrizi and Rinvoq across multiple indications, with new real-world evidence supporting expanded use in rheumatoid arthritis and psoriasis.
☑️ January 2026: Johnson & Johnson reported positive momentum for Stelara and Tremfya biosimilar strategies, enhancing access in IBD and dermatology markets.
☑️ December 2025: Pfizer Inc. expanded distribution of its NSAID and corticosteroid portfolio through major retail pharmacy partnerships, addressing rising chronic pain and inflammation needs.
☑️ December 2025: Amgen advanced its anti-inflammatory biosimilars, securing additional formulary coverage in key U.S. health plans amid cost-control initiatives.
Japan Key Industry Developments
☑️ January 2026: Japanese authorities approved additional biosimilar versions of major TNF inhibitors, accelerating reimbursement and adoption in arthritis and IBD treatment settings.
☑️ January 2026: Takeda Pharmaceutical Company Limited and global partners showcased next-generation anti-inflammatory biologics at major immunology conferences in Tokyo, focusing on asthma and COPD applications.
☑️ December 2025: Increased utilization of oral JAK inhibitors and inhaled corticosteroids in outpatient care, driven by rising respiratory and autoimmune disease prevalence.
Key Mergers and Acquisitions
✦ In Jan 2026, Eli Lilly and Company finalized its acquisition of Ventyx Biosciences for approximately US$ 1.2 billion, adding NLRP3 inflammasome inhibitors to its anti-inflammatory pipeline for broader chronic inflammation applications.
✦ AbbVie progressed advanced negotiations to potentially acquire Revolution Medicines for over US$ 20 billion, targeting RAS pathway assets with potential benefits in inflammatory signaling modulation in Jan 2026.
✦ Sanofi continued strategic bolt-on acquisitions in immunology, integrating recent 2025 deals and positioning for new anti-inflammatory asset additions in early 2026.
Purchase the report to unlock market insights:
https://www.datamintelligence.com/buy-now-page?report=anti-inflammatory-drugs-market
Market Segmentation Analysis
By Drug Class: Anti-Inflammatory Biologics and NSAIDs dominate; followed by Corticosteroids, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), and Others.
By Application: Arthritis and Asthma hold significant shares; followed by COPD, IBD, Multiple Sclerosis, Tendonitis, and Others.
By Route of Administration: Oral leads; followed by Injection, Inhalation, and Topical.
By Distribution Channel: Hospital Pharmacies and Retail Pharmacies dominate; followed by Online Pharmacies.
Regional Insights
North America commands the largest market share in the global Anti-Inflammatory Drugs market, supported by high prevalence of chronic inflammatory diseases, advanced biologic adoption, favorable reimbursement for specialty drugs, strong clinical pipelines, and the presence of leading pharmaceutical companies continuously innovating in TNF inhibitors, IL antagonists, and JAK pathways.
Asia-Pacific remains the fastest-growing region, fueled by rapidly increasing autoimmune and respiratory disease burden, expanding healthcare infrastructure, rapid biosimilar penetration, rising patient affordability, government initiatives for chronic disease management, and growing partnerships with global players.
Growth Drivers
✦ Escalating incidence of arthritis, asthma, IBD, COPD, and other inflammatory conditions
✦ Strong demand for biologics, biosimilars, NSAIDs, and corticosteroids
✦ Advancements in targeted therapies and JAK/IL inhibitors
✦ Improving access through biosimilars and expanding distribution channels
✦ Strategic pipeline developments, regulatory approvals, and market expansions
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/anti-inflammatory-drugs-market?jd
Key Players
The market includes leading companies such as AbbVie Inc., Johnson & Johnson Services, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Novartis AG, Amgen Inc., GSK plc, Merck & Co., Inc., Bristol-Myers Squibb Company, Viatris Inc., and emerging players including UCB S.A., Rapport Therapeutics, Apogee Therapeutics, Inc., among others.
Key Highlights (Top 5 Key Players)
✦ AbbVie Inc. - Leading with Skyrizi, Rinvoq, and Humira biosimilar strategies across multiple indications.
✦ Johnson & Johnson Services, Inc. - Dominating through Stelara and Tremfya in IBD, psoriasis, and arthritis.
✦ Pfizer Inc. - Strong in NSAIDs, corticosteroids, and emerging biosimilars.
✦ Amgen Inc. - Advancing Enbrel biosimilars and next-gen anti-inflammatory agents.
✦ Novartis AG - Growing with IL-17/IL-23 inhibitors and broad respiratory portfolio.
Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd
Power your decisions with real time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anti-Inflammatory Drugs Market to Reach US$ 198.92 Billion by 2031, Driven by Rising Prevalence of Autoimmune Disorders and Biosimilar Growth | DataM Intelligence here
News-ID: 4341582 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Chronic Inflammation Treatment Market to Grow at Significant CAGR through 2031, …
According to DataM Intelligence, the global Chronic Inflammation Treatment market is expected to grow at a significant CAGR during the forecast period 2024-2031. This growth is propelled by the escalating global burden of chronic inflammatory conditions such as diabetes, cardiovascular diseases, arthritis, and COPD, increasing adoption of NSAIDs, statins, and corticosteroids, growing interest in novel NLRP3 inhibitors and targeted biologics, rising use of herbal supplements and combination therapies, expanding patient…
Inflammatory Diseases Biologics Market to Reach US$ 157.31 Billion by 2033, Driv …
According to DataM Intelligence, the global Inflammatory Diseases Biologics market size was US$ 99.06 billion in 2024 and is expected to reach US$ 157.31 billion by 2033, growing at a CAGR of 5.3% during the forecast period 2025-2033. This growth is propelled by increasing prevalence of autoimmune and inflammatory conditions such as rheumatoid arthritis and psoriasis, strong adoption of TNF inhibitors and interleukin antagonists, rapid biosimilar approvals improving affordability, expanding…
Clinical Trial Management System Market Set for Strong Growth to USD 4.2 Billion …
The Global Clinical Trial Management System Market reached USD 1.5 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 4.2 billion by 2031. The global clinical trial management system market is expected to exhibit a CAGR of 14.6% during the forecast period (2024-2031).
Market growth is driven by the rising complexity of clinical trials, increasing R&D investments by pharmaceutical and biotech companies, and the need…
Femtech Market US$ 112.30 Billion by 2033 with 12.6% CAGR North America Leads wi …
The Global Femtech Market reached US$ 38.90 billion in 2024 and is projected to grow significantly to US$ 112.30 billion by 2033, registering a CAGR of 12.6% during the forecast period 2025-2033. This strong growth reflects increasing awareness of women's health issues, rising digital health adoption, and greater investments in technology-driven healthcare solutions tailored specifically for women.
Femtech focuses on addressing both female-specific and women-prevalent health conditions through products such as…
More Releases for Drug
Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming…
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage
Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic…
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights:
* Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029
* Global and Regional Antibody Drug Conjugate Market Insight
* Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023
* Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight
* Insight On Antibody Drug Conjugates In Clinical Trials: > 550…
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
